Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OVX836
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Osivax
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Osivax and KM Biologics Partner On Universal Flu Vaccine For Japan
Details : KM Biologics holds the exclusive license for the development, manufacturing, and commercialization of Osivax’s broad-spectrum OVX836 'universal' influenza vaccine candidates in Japan.
Brand Name : OVX836
Molecule Type : Vaccine
Upfront Cash : Undisclosed
September 10, 2024
Lead Product(s) : OVX836
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Osivax
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : KD-414
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Japan's KM Biologics Begins Clinical Trial of COVID-19 Vaccine Candidate
Details : The first volunteer was injected with the inactivated virus vaccine known as KD-414, the company said in a release. The study is a combined Phase 1 and Phase 2 trial involving 210 subjects to test the vaccine’s safety and ability to trigger an immune r...
Brand Name : KD-414
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 22, 2021
Lead Product(s) : KD-414
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
